- Home
- ZENV vs TLPH Comparison
ZENV vs TLPH Comparison
Compare ZENV & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- TLPH
- Stock Information
- Founded
- ZENV 2005
- TLPH 2005
- Country
- ZENV Brazil
- TLPH United States
- Employees
- ZENV N/A
- TLPH N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- TLPH Health Care
- Exchange
- ZENV Nasdaq
- TLPH Nasdaq
- Market Cap
- ZENV 70.8M
- TLPH 64.7M
- IPO Year
- ZENV 2021
- TLPH 2011
- Fundamental
- Price
- ZENV $1.28
- TLPH $1.30
- Analyst Decision
- ZENV
- TLPH Strong Buy
- Analyst Count
- ZENV 0
- TLPH 1
- Target Price
- ZENV N/A
- TLPH $6.00
- AVG Volume (30 Days)
- ZENV 21.8K
- TLPH 309.0K
- Earning Date
- ZENV 11-14-2025
- TLPH 11-12-2025
- Dividend Yield
- ZENV N/A
- TLPH N/A
- EPS Growth
- ZENV N/A
- TLPH N/A
- EPS
- ZENV N/A
- TLPH N/A
- Revenue
- ZENV $201,426,369.00
- TLPH $28,000.00
- Revenue This Year
- ZENV $12.75
- TLPH N/A
- Revenue Next Year
- ZENV N/A
- TLPH $14,533.26
- P/E Ratio
- ZENV N/A
- TLPH N/A
- Revenue Growth
- ZENV 24.80
- TLPH N/A
- 52 Week Low
- ZENV $1.02
- TLPH $0.38
- 52 Week High
- ZENV $3.03
- TLPH $1.45
- Technical
- Relative Strength Index (RSI)
- ZENV 46.03
- TLPH 55.89
- Support Level
- ZENV $1.29
- TLPH $1.01
- Resistance Level
- ZENV $1.46
- TLPH $1.35
- Average True Range (ATR)
- ZENV 0.11
- TLPH 0.11
- MACD
- ZENV 0.01
- TLPH -0.01
- Stochastic Oscillator
- ZENV 57.14
- TLPH 73.17
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.